File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Initial attributable cost and economic burden of clinically-relevant differentiated thyroid cancer: a health care service provider perspective

TitleInitial attributable cost and economic burden of clinically-relevant differentiated thyroid cancer: a health care service provider perspective
Authors
Issue Date2015
PublisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/ejso
Citation
European Journal of Surgical Oncology, 2015, v. 41 n. 6, p. 758-765 How to Cite?
AbstractBackground Rapid rise in differentiated thyroid cancer (DTC) may impose a heavy economic burden on future healthcare. We aimed to calculate the average first-year monetary cost/patient for DTC and estimate the projected cost burden on our local healthcare system. Methods Medical records of 270 clinically-relevant DTC patients were reviewed to calculate the amount of services utilized during the first-year. Only direct costs were included with estimates derived from government gazette. Cancer incidences were derived from the territory-wide cancer registry. Total annual cost equaled to the incidence multiplied by the cost/patient. Results The average first-year cost of DTC was USD11,560/patient. Initial surgery accounted for 66.9% of total cost. Male and female annual percentage increases for DTC were 4.86% and 4.28%, respectively. Female DTC is projected to surpass rectal cancer in 2019 (20.4/100,000 vs. 20.0/100,000) and colon cancer (47.2/100,000 vs. 46.8/100,000) in 2039. However, the projected incidence of DTC in 2026 would still be about one fourth that of CRC (19.5/100,000 vs. 83.2/100,000). Conclusions The average first-year monetary cost of DTC care was relatively low. Initial surgery accounted for most of the cost. Despite a rapid incidence rise, the projected first-year cost for DTC is unlikely to impose substantial economic burden on our local future healthcare system.
Persistent Identifierhttp://hdl.handle.net/10722/208730
ISSN
2015 Impact Factor: 2.94
2015 SCImago Journal Rankings: 1.327

 

DC FieldValueLanguage
dc.contributor.authorLang, HHB-
dc.contributor.authorWong, KH-
dc.contributor.authorChan, TYC-
dc.date.accessioned2015-03-18T09:07:05Z-
dc.date.available2015-03-18T09:07:05Z-
dc.date.issued2015-
dc.identifier.citationEuropean Journal of Surgical Oncology, 2015, v. 41 n. 6, p. 758-765-
dc.identifier.issn0748-7983-
dc.identifier.urihttp://hdl.handle.net/10722/208730-
dc.description.abstractBackground Rapid rise in differentiated thyroid cancer (DTC) may impose a heavy economic burden on future healthcare. We aimed to calculate the average first-year monetary cost/patient for DTC and estimate the projected cost burden on our local healthcare system. Methods Medical records of 270 clinically-relevant DTC patients were reviewed to calculate the amount of services utilized during the first-year. Only direct costs were included with estimates derived from government gazette. Cancer incidences were derived from the territory-wide cancer registry. Total annual cost equaled to the incidence multiplied by the cost/patient. Results The average first-year cost of DTC was USD11,560/patient. Initial surgery accounted for 66.9% of total cost. Male and female annual percentage increases for DTC were 4.86% and 4.28%, respectively. Female DTC is projected to surpass rectal cancer in 2019 (20.4/100,000 vs. 20.0/100,000) and colon cancer (47.2/100,000 vs. 46.8/100,000) in 2039. However, the projected incidence of DTC in 2026 would still be about one fourth that of CRC (19.5/100,000 vs. 83.2/100,000). Conclusions The average first-year monetary cost of DTC care was relatively low. Initial surgery accounted for most of the cost. Despite a rapid incidence rise, the projected first-year cost for DTC is unlikely to impose substantial economic burden on our local future healthcare system.-
dc.languageeng-
dc.publisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/ejso-
dc.relation.ispartofEuropean Journal of Surgical Oncology-
dc.titleInitial attributable cost and economic burden of clinically-relevant differentiated thyroid cancer: a health care service provider perspective-
dc.typeArticle-
dc.identifier.emailLang, HHB: Blang@hku.hk-
dc.identifier.emailWong, KH: carlosho@hku.hk-
dc.identifier.authorityLang, HHB=rp01828-
dc.identifier.authorityWong, KH=rp01931-
dc.identifier.doi10.1016/j.ejso.2015.01.019-
dc.identifier.pmid25680952-
dc.identifier.scopuseid_2-s2.0-84929134498-
dc.identifier.hkuros242608-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats